INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
1 .- 25 . (canceled)
26 . A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
27 . A pharmaceutical composition comprising the compound of claim 26 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
28 . A method of treating a condition mediated by FGFR-4, comprising administering a therapeutically effective amount of the compound of claim 26 , or a pharmaceutically acceptable salt thereof, to a subject.
29 . A method of treating a condition characterized by overexpression of FGFR-4, comprising administering a therapeutically effective amount of the compound of claim 26 , or a pharmaceutically acceptable salt thereof, to a subject.
30 . A method of treating a condition characterized by amplified FGF-19, comprising administering a therapeutically effective amount of the compound of claim 26 , or a pharmaceutically acceptable salt thereof, to a subject.
31 . A method of treating a condition characterized by overexpression of FGF-19, comprising administering a therapeutically effective amount of the compound of claim 26 , or a pharmaceutically acceptable salt thereof, to a subject.
32 . A method of treating cancer, the method comprising administering to a subject a therapeutically effective amount of the compound of claim 26 , or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from the group consisting of liver cancer, breast cancer, lung cancer, ovarian cancer, and a sarcoma.
33 . A method of treating hepatocellular carcinoma, the method comprising administering to a subject a therapeutically effective amount of the compound of claim 26 , or a pharmaceutically acceptable salt thereof.
34 . A method of treating hyperlipidemia, the method comprising administering to a subject a therapeutically effective amount of the compound of claim 26 , or a pharmaceutically acceptable salt thereof.